Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Рынки
Скринер
Новости
О нас

ZVRA - Zevra Therapeutics, Inc. Последние новости | Finranks

Home

ZVRA

Z

Zevra Therapeutics, Inc. (ZVRA)

NMS – Цена в реальном времени. Валюта: USD

9.16

-0.24 (-2.55%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

9.31

+0.15 (1.64%)

После закрытия: Mar 27, 2026, 7:59 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)

Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, March 20, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that the Company has granted as of March 18, 2026 an equity inducement award to Justin Renz, the Company's new Chief Financial Officer pursuant to the Company's 2023 Employment Inducement Award Plan (as amended and/or restated, the “Inducement Award Plan”). The equity award was approved by the Compensation Committee of the Board of Directors in accordance with Nasdaq Rule 5635(c)(4) and made as a material inducement to Mr. Renz upon acceptance of employment with Zevra.

Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million

Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million

BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced an agreement under which Commave Therapeutics SA (Commave) will purchase Zevra's serdexmethylphenidate (SDX) portfolio, including AZSTARYS® and KP1077, for $50 million. "We are pleased to have reached a mutually beneficial agreement with Commave regarding the sale of our entire SDX portfolio," said Neil F.

Why Zevra Therapeutics Stock Zoomed 21% Higher Today

Why Zevra Therapeutics Stock Zoomed 21% Higher Today

It also posted 44% net revenue growth for the period. Both headline figures crushed the consensus analyst estimates.

Zevra Therapeutics: Miplyffa Uptake Validates Rare Disease Commercial Model

Zevra Therapeutics: Miplyffa Uptake Validates Rare Disease Commercial Model

Zevra Therapeutics delivered robust FY25 results, with 350% revenue growth to $106.5M and a GAAP EPS of $1.40, driven by Miplyffa's commercial launch. Miplyffa's rapid adoption in the ultra-rare NPC market, supported by expanded payer coverage and diagnostic initiatives, underpins ZVRA's strong commercial momentum. ZVRA trades at discounted valuation multiples (16.9x forward P/E, 10.7x EV/EBIT), reflecting market caution over one-time income and earnings sustainability.

Zevra Therapeutics, Inc. (ZVRA) Q4 2025 Earnings Call Transcript

Zevra Therapeutics, Inc. (ZVRA) Q4 2025 Earnings Call Transcript

Zevra Therapeutics, Inc. (ZVRA) Q4 2025 Earnings Call Transcript

Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call

Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call

CELEBRATION, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced it will report corporate and financial results for the fourth quarter and full year 2025 on Monday, March 9, 2026, via a news release after the market close, and will host a conference call/audio webcast at 4:30 p.m. ET that day.

Zevra Therapeutics to Present at the Citizens Life Sciences Conference

Zevra Therapeutics to Present at the Citizens Life Sciences Conference

CELEBRATION, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra's executive leadership team will present at the Citizens Life Sciences Conference in Miami Beach, FL on Wednesday, March 11, 2026, at 9:00 a.m. ET.

Видео

No Data

There is no data to display

Пресс-релизы

Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)

Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, March 20, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that the Company has granted as of March 18, 2026 an equity inducement award to Justin Renz, the Company's new Chief Financial Officer pursuant to the Company's 2023 Employment Inducement Award Plan (as amended and/or restated, the “Inducement Award Plan”). The equity award was approved by the Compensation Committee of the Board of Directors in accordance with Nasdaq Rule 5635(c)(4) and made as a material inducement to Mr. Renz upon acceptance of employment with Zevra.

Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million

Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million

BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced an agreement under which Commave Therapeutics SA (Commave) will purchase Zevra's serdexmethylphenidate (SDX) portfolio, including AZSTARYS® and KP1077, for $50 million. "We are pleased to have reached a mutually beneficial agreement with Commave regarding the sale of our entire SDX portfolio," said Neil F.

Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call

Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call

CELEBRATION, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced it will report corporate and financial results for the fourth quarter and full year 2025 on Monday, March 9, 2026, via a news release after the market close, and will host a conference call/audio webcast at 4:30 p.m. ET that day.

Transpire Bio Strengthens its Leadership Team with Appointment of LaDuane Clifton as Chief Financial Officer

Transpire Bio Strengthens its Leadership Team with Appointment of LaDuane Clifton as Chief Financial Officer

SUNRISE, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announced the appointment of R. LaDuane Clifton as Chief Financial Officer (CFO).